检索结果-南通市图书馆

Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy

引用

Gastroenterology Report 2022年第1期10卷 370-376页

作者： natsuki ishida Yusuke Asai Takahiro Miyazu Satoshi Tamura Shinya Tani Mihoko Yamade Moriya Iwaizumi Yasushi Hamaya Satoshi Osawa Takahisa Furuta Ken Sugimoto First Department of Medicine Hamamatsu University School of MedicineHamamatsuShizuokaJapan Department of Endoscopic and Photodynamic Medicine Hamamatsu University School of MedicineHamamatsuShizuokaJapan Department of Laboratory Medicine Hamamatsu University School of MedicineHamamatsuShizuokaJapan Center for Clinical Research Hamamatsu University School of MedicineHamamatsuShizuokaJapan

Advanced therapies for patients with mild-to-severe ulcerative colitis(UC)may result in treatment failure.We examined whether the lymphocyte-to-monocyte ratio(L/M ratio)could predict the failure of advanced therapies.This retrospective,observational,cohort study included 73 patients who were treated with advanced therapies at the Hamamatsu University School of Medicine(Shizuoka,Japan)between February 2011 and November 2020.The patients were divided into the nonfailure and failure groups,and their leukocyte counts and ratios before induction were examined.Univariate and multivariate analyses were performed to identify the prognostic factors.Advanced therapies failed within 3 months in 15(20.5%)patients.Only the L/M ratio was significantly lower in the failure group than in the non-failure group(P=0.004).Receiveroperating characteristic(ROC)curve analysis revealed that an L/M ratio of ≤3.417 was predictive of treatment failure;the area under the curve(AUC)was 0.747(95%CI,0.620–0.874).Kaplan–Meier analysis revealed that the failure-free rate was significantly lower in the group with an L/M ratio of≤3.417 than in the group with an L/M ratio of>3.417(log-rank test P=0.002).Cox proportional hazard regression analysis identified an L/M ratio of≤3.417 as an independent risk factor for failure within 3 months after the induction of advanced therapies.Furthermore,ROC analysis of patients who did not receive immunomodulators also revealed that the cut-off L/M ratio was 3.417 and the AUC was 0.796(95%CI,0.666–0.925).In patients receiving advanced therapies for active UC,the L/M ratio can predict treatment failure within 3 months.L/M ratios could facilitate the transition from advanced therapies to subsequent treatments.

关键词： advanced therapy failure lymphocyte-to-monocyte ratio ulcerative colitis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Intrahepatic cholangiocarcinoma in patients with primary sclerosing cholangitis and ulcerative colitis: Two case reports

引用

World Journal of Gastrointestinal Surgery 2023年第6期15卷 1224-1231页

作者： Takahiro Miyazu natsuki ishida Yusuke Asai Satoshi Tamura Shinya Tani Mihoko Yamade Moriya Iwaizumi Yasushi Hamaya Satoshi Osawa Satoshi Baba Ken Sugimoto First Department of Medicine Hamamatsu University School of MedicineHamamatsu 431-3192Japan Department of Endoscopic and Photodynamic Medicine Hamamatsu University School of MedicineHamamatsu 431-3192Japan Department of Laboratory Medicine Hamamatsu University School of MedicineHamamatsu 431-3192Japan Department of Diagnostic Pathology Hamamatsu University School of MedicineHamamatsu 431-3192Japan

BACKGROUND Primary sclerosing cholangitis(PSC)is an extraintestinal manifestation of ulcerative colitis(UC).PSC is a well-known risk factor for intrahepatic cholangiocarcinoma(ICC),and ICC is known to have a poor prognosis.CASE SUMMARY We present two cases of ICC in patients with PSC associated with UC.In the first case,a tumor was found by magnetic resonance imaging(MRI)in the liver of a patient with PSC and UC who presented to our hospital with right-sided rib pain.The second patient was asymptomatic,but we unexpectedly detected two liver tumors in an MRI performed to evaluate bile duct stenosis associated with PSC.ICC was strongly suspected by computed tomography and MRI in both cases,and surgery was performed,but unfortunately,the first patient died of ICC recurrence 16 mo postoperatively,and the second patient died of liver failure 14 mo postoperatively.CONCLUSION Careful follow-up of patients with UC and PSC with imaging and blood tests is necessary for early detection of ICC.

关键词： Ulcerative colitis Primary sclerosing cholangitis Intrahepatic cholangiocarcinoma Hepatic lobectomy Inflammatory bowel disease Case report

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Comparison of fecal calprotectin levels and endoscopic scores for predicting relapse in patients with ulcerative colitis in remission

引用

World Journal of Gastroenterology 2023年第47期29卷 6111-6121页

作者： natsuki ishida Tatsuhiro Ito Kenichi Takahashi Yusuke Asai Takahiro Miyazu Tomohiro Higuchi Satoshi Tamura Shinya Tani Mihoko Yamade Moriya Iwaizumi Yasushi Hamaya Satoshi Osawa Ken Sugimoto Department of Endoscopic and Photodynamic Medicine Hamamatsu University of School of MedicineHamamatsu 431-3192Japan First Department of Medicine Hamamatsu University of School of MedicineHamamatsu 431-3192Japan Department of Laboratory Medicine Hamamatsu University of School of MedicineHamamatsu 431-3192Japan

BACKGROUND Although the usefulness of endoscopic scores,such as the Mayo Endoscopic Subscore(MES),Ulcerative Colitis Endoscopic Index of Severity(UCEIS),and Ulcerative Colitis Colonoscopic Index of Severity(UCCIS),and biomarkers such as fecal calprotectin(FC)for predicting relapse in ulcerative colitis(UC)has been reported,few studies have included endoscopic scores for evaluating the entire colon.AIM To compare the usefulness of FC value and MES,UCEIS,and UCCIS for predicting relapse in patients with UC in clinical remission.METHODS In total,75 patients with UC in clinical and endoscopic remission who visited our institution between February 2019 and March 2022 were enrolled.The diagnosis of UC was confirmed based on the clinical presentation,endoscopic findings,and histology,according to the current established criteria for UC.Fecal samples were collected the day before or after the colonoscopy for measurement of FC.Endoscopic evaluations were performed using MES,UCEIS,and UCCIS.The primary outcome measure of this study was the assessment of the association between relapse within 12 mo and MES,UCEIS,UCCIS,and FC.The secondary outcome was the comparison between endoscopic scores and biomarkers in en-rolled patients with UC with mucosal healing.RESULTSFC and UCCIS showed a significant correlation with UCEIS (r = 0.537, P < 0.001 and r = 0.957, P < 0.001, respectively).Receiver-operating characteristic analysis for predicting MES 0 showed that the area under the curve ofUCCIS was significantly higher than that of FC (P < 0.01). During the 1-year observation period, 18 (24%) patientsexperienced a relapse, and both the FC and UCCIS of the relapse group were significantly higher than that of theremission group. The cut-off values for predicting relapse were set at FC = 323 mg/kg and UCCIS = 10.2. The areaunder the curve of the receiver-operating characteristic analysis for predicting relapse did not show a significantdifference between FC and UCCIS. The accuracy of the endoscopic scores and biomarkers in predicting r

关键词： Ulcerative colitis Mayo Endoscopic Subscore Ulcerative Colitis Endoscopic Index of Severity Ulcerative Colitis Colonoscopic Index of Severity Fecal calprotectin Relapse

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome

引用

World Journal of Gastroenterology 2021年第22期27卷 3109-3120页

作者： natsuki ishida Takahiro Miyazu Satoshi Tamura Shinya Tani Mihoko Yamade Moriya Iwaizumi Yasushi Hamaya Satoshi Osawa Takahisa Furuta Ken Sugimoto First Department of Medicine Hamamatsu University of School of MedicineHamamatsu 431-3192Japan Department of Laboratory Medicine Hamamatsu University of School of MedicineHamamatsu 431-3192Japan Department of Endoscopic and Photodynamic Medicine Hamamatsu University of School of MedicineHamamatsu 431-3192Japan Center for Clinical Research Hamamatsu University of School of MedicineHamamatsu 43131Japan

BACKGROUND Oral tacrolimus is a therapeutic agent for moderate to severe steroid-dependent or resistant ulcerative colitis(UC),but remission induction is difficult,and it is necessary to treat the patient while considering the next treatment.AIM To examine serum albumin(Alb)level as a prognostic factor for the therapeutic effect of tacrolimus in clinical practice.METHODS Forty-seven patients with UC treated with tacrolimus at our institution were divided into remission and failure groups(colectomy or switch to biologics),and the biological data at the start of observation and at weeks 1 and 2 were retrospectively examined.Kaplan-Meier and multivariate analyses were performed using Alb as a prognostic factor in UC treatment.RESULTS During the three months observed,17(36.2%)patients failed treatment with tacrolimus.A comparison between the failure and remission groups showed a significant difference only in Alb in week 2,and in the week 2/week 0 Alb ratio,which showed the rate of change in Alb.The cut-off value of the week 2/week 0 Alb ratio that predicted failure was 1,and its area under the curve was 0.751(95%CI:0.604-0.898).In the Kaplan-Meier analysis,a week 2/week 0 Alb ratio≤1 had a significantly higher failure rate than that of>1;Cox proportional hazard regression analysis also showed that a week 2/week 0 Alb ratio≤1 was an independent prognostic factor for failure within 3 mo after the start of tacrolimus treatment.CONCLUSION A week 2/week 0 Alb ratio≤1 predicts failure within 3 mo of tacrolimus administration for UC.High failure risk exists with week 2 Alb values≤1 on admission.

关键词： Ulcerative colitis Tacrolimus Albumin

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Evaluating mucosal healing using colon capsule endoscopy predicts outcome in patients with ulcerative colitis in clinical remission

引用

World Journal of Clinical Cases 2018年第15期6卷 952-960页

作者： Ryosuke Takano Satoshi Osawa Takahiro Uotani Shinya Tani natsuki ishida Satoshi Tamura Mihoko Yamade Moriya Iwaizumi Yasushi Hamaya Takahisa Furuta Hiroaki Miyajima Ken Sugimoto First Department of Medicine Hamamatsu University School of Medicine Department of Endoscopic and Photodynamic Medicine Hamamatsu University School of Medicine Department of Laboratory Medicine Hamamatsu University School of Medicine Center for Clinical Research Hamamatsu University School of Medicine

AIM To examine whether second generation of colon capsule endoscopy(CCE-2) is acceptable for assessing the severity of mucosal inflammation and evaluating mucosal healing using CCE-2 is able to predict outcome in ulcerative colitis(UC) patients, especially in clinical remission.METHODS A total of 30 consecutive UC patients in clinical remission were enrolled to undergo CCE-2. Clinical remission was defined as clinical activity index(CAI) ≤ 4 according to Rachmilewitz index. The rate of total colon observation and colon cleansing level were evaluated. Severity of mucosal inflammation in UC was assessed according to the Mayo endoscopic subscore(MES) and Ulcerative Colitis Endoscopic Index of Severity(UCEIS). Relapsefree survival was assessed. Acceptability of CCE-2 was assessed using a questionnaire survey.RESULTS The rate of total colon observation within its battery life was 93.3%. The proportion of "excellent" plus "good" cleansing level was 73.3%. The rate of mucosal healing(MES 0, 1) assessed by CCE-2 was 77.0%. The relapse-free survival rate was significantly higher in MES 0, 1 than in MES 2, 3(P = 0.0435), and in UCEIS 0-3 than in UCEIS 4-8(P = 0.0211), whereas there was no significant difference between CAI 0 and CAI 1-4 groups. A questionnaire survey revealed an overall acceptability of CCE.CONCLUSION CCE-2 is acceptable for assessing the severity of mucosal inflammation in UC patients, especially in clinical remission. Evaluating mucosal healing using CCE-2 was able to predict outcome.

关键词： Colon capsule endoscopy Ulcerative colitis Mucosal healing Mayo endoscopic subscore Ulcerative Colitis Endoscopic Index of Severity

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Tuberous sclerosis patient with neuroendocrine carcinoma of the esophagogastric junction:A case report

引用

World Journal of Gastroenterology 2020年第45期26卷 7263-7271页

作者： natsuki ishida Takahiro Miyazu Satoshi Tamura Satoshi Suzuki Shinya Tani Mihoko Yamade Moriya Iwaizumi Satoshi Osawa Yasushi Hamaya Kazuya Shinmura Haruhiko Sugimura Katsutoshi Miura Takahisa Furuta Ken Sugimoto First Department of Medicine Hamamatsu University School of MedicineHamamatsu 431-3192Japan Department of Endoscopic and Photodynamic Medicine Hamamatsu University School of MedicineHamamatsu 431-3192Japan Department of Laboratory Medicine Hamamatsu University School of MedicineHamamatsu 431-3192Japan Haruhiko Sugimura Department of Tumor PathologyHamamatsu University School of MedicineHamamatsu 431-3192Japan Department of Health Science Hamamatsu University School of MedicineHamamatsu 431-3192Japan Center for Clinical Research Hamamatsu University School of MedicineHamamatsu 431-3192Japan

BACKGROUND Tuberous sclerosis complex(TSC)is a rare inherited disease with non-cancerous tumor growths in the skin,brain,kidneys,heart,and lungs.The co-occurrence of neuroendocrine neoplasm(NEN)with TSC is even rarer.There have been few reports on the relationship between TSC and neuroendocrine tumors(NETs),and fewer on the relationship between TSC and neuroendocrine carcinoma(NEC),a subtype of NEN.This is the first reported case of NEC occurring at the esophagogastric junction in a patient with TSC.CASE SUMMARY A 46-year-old woman visiting our hospital for the treatment of TSC was admitted to the emergency department with tarry stools and dizziness.Computed tomography scans revealed thickness of the gastric cardia,multiple metastatic lesions of the liver,and enlarged lymph nodes near the lesser curvature of the stomach.Esophagogastroduodenoscopy revealed a type 3 tumor located from the esophagogastric junction to the fundus,and the pathological diagnosis by biopsy was NEC.The patient was treated with seven courses of cisplatin+irinotecan,followed by eight courses of ramucirumab+nab-paclitaxel,one course of nivolumab,and two courses of S-1+oxaliplatin.Twenty-three months after the first treatment,the patient died because of disease progression and deterioration of the general condition.CONCLUSION This case of NEC occurring in a patient with TSC indicates a difference in the occurrence of NETs and NECs.

关键词： Tuberous sclerosis complex Neuroendocrine carcinoma Neuroendocrine tumor mTOR inhibitor Esophagogastric junction Chemotherapy Case report

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：